Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q1 2019 Earnings Conference Call Transcript
May 10, 2019 • 08:30 am ET
Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Ocular Therapeutix First Quarter Earnings Conference call. At this time all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time.
It is now my pleasure to turn the call over to Donald Notman, Chief Financial Officer of Ocular Therapeutix. Please go ahead, sir.
Thank you, Liz. Good morning, everyone, and thank you for joining us on our first quarter 2019 financial results and business update conference call. This morning, we issued a press release providing an update on the Company's product development programs and details of the Company's financial results for the quarter ended March 31, 2019. The press release can be accessed on the Investors portion of our website at investors.ocutx.com.
Leading the call today, will be Antony Mattessich, our President and Chief Executive Officer, who will provide an update on plans for the upcoming commercial launch of DEXTENZA and a summary of our corporate developments and upcoming clinical milestones. Also speaking on the call will be Dr. Michael Goldstein, our Chief Medical Officer, who will provide an update on our clinical developments and pipelines. Following Michael's remarks, I'll provide an overview of the financial highlights for the first quarter 2019 before turning the call back over to Antony for a summary and questions.
For Q&A, we will also be joined by Scott Corning, our Senior Vice President, Commercial; and Dr. Dan Bollag, our Chief Strategy Officer and Head of Regulatory Affairs.
As a reminder, during today's call, we will be making certain forward-looking statements. Various remarks that we make during this call about the Company's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the risk factors section of our most recent quarterly report on Form 10-Q, which is filed with the SEC on May 10, 2019.
In addition, any forward-looking statements represent our views only as of today, and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, except as we are required to do so by law, even if our views change.
I'll now turn the call over to Antony.
Thanks, Donald. This is an incredibly exciting time at Ocular. The launch of DEXTENZA, our dexamethasone intracanalicular insert for the treatment of post-surgical pain is in full rollout. Commercial product is now at the distributors. Our field force is fully trained and has been calling on accounts since April 29. And most importantly, samples should be reaching the first surgery centers early next week, giving surgeons the ability to work DEXTENZA into their surgical protocols.